Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy
Clinical Stage Cell Therapy Company Reports Concurrent Modulation of T Regulatory Cells and Tolerogenic Dendritic Cells using Adoptive Cellular Therapy
News provided by
Share this article
Share this article
PHOENIX, Dec. 10, 2020 /PRNewswire/ Creative Medical Technology Holdings trading under the ticker symbol CELZ announced today its patent filing based on data covering utilization of the Company s ImmCelz
® product at generating what is termed in the field of immunology as infectious tolerance.
Using an animal model of rheumatoid arthritis, investigators demonstrated administration of ImmCel